{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:55:35Z","timestamp":1791924935382,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ijantimicag.2015.04.010","type":"journal-article","created":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T02:22:10Z","timestamp":1433557330000},"page":"242-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Fluoroquinolones or macrolides alone versus combined with \u03b2-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis"],"prefix":"10.1016","volume":"46","author":[{"given":"Ayelet","family":"Raz-Pasteur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mical","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0150","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious diseases society of America\/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0155","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","article-title":"Pneumonia guidelines committee of the BTS standards of care committee BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.idc.2012.11.004","article-title":"Does empirical therapy with a fluoroquinolone or the combination of a \u03b2-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?","volume":"27","author":"Ruhe","year":"2013","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0165","series-title":"Cochrane handbook for systematic reviews of interventions. Version 5.1.0","year":"2011"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0170","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","article-title":"Antibiotic treatment strategies for community-acquired pneumonia in adults","volume":"372","author":"Postma","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0175","first-page":"2558","article-title":"Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia","volume":"38","author":"Etemadi","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0180","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0149-2918(02)80034-0","article-title":"A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia","volume":"24","author":"Frank","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0185","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/BF03261911","article-title":"High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study","volume":"32","author":"Lee","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0190","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1378\/chest.128.1.172","article-title":"Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors","volume":"128","author":"Leroy","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0195","first-page":"321","article-title":"An open-label, randomized comparison of levofloxacin and amoxicillin\/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia","volume":"30","author":"Lin","year":"2007","journal-title":"Chang Gung Med J"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0200","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10096-005-1347-1","article-title":"Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors","volume":"24","author":"Portier","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/37.suppl_A.83","article-title":"Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French study group","volume":"37","author":"Portier","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0210","series-title":"Proceedings of the European Respiratory Society 13th Annual Congress","article-title":"No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo","author":"Ramirez","year":"2003"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0215","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1086\/587519","article-title":"Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study\u2014a randomized clinical trial","volume":"46","author":"Torres","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0220","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/archinte.160.9.1294","article-title":"Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial","volume":"160","author":"Vergis","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0225","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11596-006-0411-0","article-title":"Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia","volume":"26","author":"Xu","year":"2006","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0230","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00151829-200403050-00006","article-title":"Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia","volume":"3","author":"Zervos","year":"2004","journal-title":"Treat Respir Med"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0235","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/378406","volume":"38","author":"Fogarty","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0240","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000029424","article-title":"Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime","volume":"66","author":"Rovira","year":"1999","journal-title":"Respiration"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0245","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00044011-199714060-00001","article-title":"Clarithromycin vs combined cefuroxime and erythromycin in the treatment of hospitalised community-acquired pneumonia patients\u2014intravenous followed by oral therapy","volume":"14","author":"Vetter","year":"1997","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0250","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1503\/cmaj.080358","article-title":"Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials","volume":"179","author":"Vardakas","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0255","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1469-0691.2012.03838.x","article-title":"Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials","volume":"19","author":"Skalsky","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0260","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"55","author":"Asadi","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0265","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0270","first-page":"CD004418","article-title":"Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults","volume":"9","author":"Eliakim-Raz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0275","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1128\/AAC.02039-13","article-title":"Antibiotic utilization for acute respiratory tract infections in U.S. emergency departments","volume":"58","author":"Donnelly","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0280","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/jac\/dkr555","article-title":"Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study","volume":"67","author":"Lafaurie","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0285","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1128\/AAC.00237-11","article-title":"Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada","volume":"55","author":"Patel","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.04.010_bib0290","series-title":"Mandell, Douglas, and Bennett's principles and practice of infectious diseases","author":"Bennett","year":"2015"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915001867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915001867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T02:58:52Z","timestamp":1537585132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857915001867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0924857915001867"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.04.010","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluoroquinolones or macrolides alone versus combined with \u03b2-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}